Nicholas G Nickols, Zhibao Mi, Ellen DeMatt, Kousick Biswas, Christina E Clise, John T Huggins, Spyridoula Maraka, Elena Ambrogini, Mehdi S Mirsaeidi, Ellis R Levin, Daniel J Becker, Danil V Makarov, Victor Adorno Febles, Pooja M Belligund, Mohammad Al-Ajam, Muthiah P Muthiah, Robert B Montgomery, Kyle W Robinson, Yu-Ning Wong, Roger J Bedimo, Reina C Villareal, Samuel M Aguayo, Martin W Schoen, Matthew B Goetz, Christopher J Graber, Debika Bhattacharya, Guy Soo Hoo, Greg Orshansky, Leslie E Norman, Samantha Tran, Leila Ghayouri, Sonny Tsai, Michelle Geelhoed, Mathew B Rettig
Importance: SARS-CoV-2 entry requires the TMPRSS2 cell surface protease. Antiandrogen therapies reduce expression of TMPRSS2. Objective: To determine if temporary androgen suppression induced by degarelix improves clinical outcomes of inpatients hospitalized with COVID-19. Design, Setting, and Participants: The Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH) phase 2, placebo-controlled, double-blind, randomized clinical trial compared efficacy of degarelix plus standard care vs placebo plus standard care on clinical outcomes in men hospitalized with COVID-19 but not requiring invasive mechanical ventilation...
April 1, 2022: JAMA Network Open